Condition: Acute Myeloid Leukemia (AML) · Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases · Myelodysplatic Syndromes · Sponsor: Caris Science, Inc.
The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
This description comes directly from the study's public registry record.
Mary Baker · 602-571-2771 · carisresearch@carisls.com
Harshita Mittal · 617-862-1263 · hmittal@carisls.com
Always discuss trial participation with your own doctor first.
| Caris Life Sciences | Phoenix, Arizona, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07680868